APAC Healthcare Weekly (August 30)– CSPC Pharma, Akeso, Takeda, Astellas, Hanmi Pharm, SK Biopharma
CSPC and Akeso announced positive results from their respective Phase 3 trials for cancer drug candidates. Takeda got FDA approval for blood cancer...
103 Views
GC Biopharma (006280 KS/Buy)4Q25 preview: Alyglo growth to ease concerns
We estimate that Alyglo revenue rose to around W70bn, supported by expanded prescriptions and inventory stocking, which likely contributed to...
138 Views
GC Biopharma (006280 KS/Buy)3Q25 Review: In-Line Results
For 3Q25, GC Biopharma posted revenue of W609.5bn (+31.1% YoY), beating the consensus (W520.2bn). Top-line growth was driven by: 1) higher sales of...
198 Views
APAC Healthcare Weekly (May 31) – Innovent Biologics, Junshi Bio, Henlius Bio, Olympus, GC Bio
Innovent stuck $10.5B outlicensing deal with Pfizer. Olympus will acquire BioProtect. Eli Lilly is acquiring GC Bio’s US affiliate. Dong-A’s...
159 Views
APAC Healthcare Weekly (May 17) – Hengrui, Sino Bio, BeOne, Otsuka, Celltrion, Bora Pharmaceuticals
Hengrui stuck licensing agreement with BMS. Sino Bio enters exclusive collaboration with GSK. BeOne got FDA approval for new drug. Bora will...
134 Views